Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: April 24, 2025
Reporting Period: First Quarter of 2025
This filing serves as a notification that the Company issued an Earnings Press Release and a presentation regarding its financial results for the first quarter of 2025. The detailed financial data is contained within the exhibits (Exhibit 99.1 and 99.2) incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the 8-K filing and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are disclosed in the attached Earnings Press Release (Exhibit 99.1) and Presentation Materials (Exhibit 99.2), which are not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It only confirms that the Company announced its Q1 2025 results on April 24, 2025.
Guidance, Outlook, and Risks
- Disclosure: The Company posted a presentation on its website regarding financial and operating initiatives available during the conference call.
- Non-GAAP Measures: The Earnings Press Release and Presentation include non-GAAP financial information. Reconciliations to GAAP measures are available in Exhibit 99.1.
- Legal Status: The information in Item 7.01 (Regulation FD Disclosure) is not deemed "filed" under the Exchange Act and is not subject to Section 18 liabilities, nor is it incorporated by reference into future filings unless specifically stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Earnings Press Release) for specific Q1 2025 revenue, net income, and EPS figures.
- Examine Exhibit 99.2 (Presentation Materials) for management commentary on operating initiatives and future outlook.
- Verify the reconciliation between non-GAAP and GAAP financial measures provided in the press release.
- Confirm the status of the 1.000% Notes due 2025 listed in the securities section, given the filing date is April 2025.